Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study

Novartis (NVS) announced positive data on the cholesterol drug Leqvio (inclisiran) from the late-stage VMONO study. Leqvio is the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C). The drug is administered as a subcutaneous injection with an initial dose, another at three months, and then every six months. The drug is approved in several countries, including the United States, EU, Japan and China. Shares of Novartis have risen 18.8% year to date compar ...